Growing Body of Evidence Highlights Potential Applications for Liquid Biopsy in Clinical Practice
Erin JungmeyerDuring a lecture at NACLC 22, Dr. Christian Rolfo illustrated how ctDNA could be used to monitor progression and inform treatment decisions. Read more
IASLC Leadership Shares Experiences, Offers Advice for Women in Thoracic Oncology
Erin JungmeyerDuring a networking panel at NACLC 22, CEO Karen Kelly and President Heather Wakelee joined program co-chairs Drs. Jessica Donington, Marina Chiara Garassino, and Jyoti Patel for a discussion with other women in the field. Read more
When Perfect is the Enemy of Good: Investigators Compare Rigorous Clinical Trial Data to Real-World Experience
Kamya Sankar, MD+more
Using a real-world cohort of US veterans, researchers examine the effectiveness of durvalumab consolidation in unresectable stage III NSCLC. Read more
Public Interest in Complementary, Alternative Approaches to Smoking Cessation Growing
Deepti Behl, MDWhile evidence is mixed on the efficacy of some non-traditional methods, Dr. Deepti Behl says lung cancer physicians should be familiar with the options and support patients who are willing to try to stop smoking. Read more
Upcoming IASLC meetings offer educational opportunities around the globe. Read more for registration and abstract news from LACLC, ACLC, and TTLC. Read more
NACLC 22 Educational Session Explores the Rationale for Immune Checkpoint Inhibition
Erin JungmeyerDuring IASLC’s North America Conference on Lung Cancer, MD Anderson’s Dr. Tina Cascone reviewed the evidence for neoadjuvant and adjuvant therapy in NSCLC. Read more
Researcher Reveals How Air Pollution May Cause Lung Cancer
Erin JungmeyerDuring ESMO Congress 2022, Prof. Charles Swanton shared data that show cells with EGFR and KRAS gene mutations can turn cancerous when exposed to pollution from the burning of fossil fuels. Read more
Former IASLC board member Dr. Carolyn Dresler recently honored for her lifetime of tobacco control advocacy. Penn Medicine chosen as site for US National Cancer Institute Telehealth Research Center of Excellence. Read more
KEYNOTE-604 Follow-Up Results Continue to Show Clinically Meaningful Improvement
Cody HoltLong-term data presented by Dr. Charles Rudin during WCLC 2022 showed significant OS benefit for patients with extensive stage SCLC on pembrolizumab combination versus placebo. Read more
Study Shows Shorter-Term Assessments Underestimate Pollution Exposure
Cody HoltDuring WCLC 22, Dr. Renelle Myers demonstrated the importance of considering long-term cumulative exposure to air pollutants when assessing individual lung cancer risk. Read more